Evommune doses first patient in Phase 2b trial of EVO756 for migraine prevention

Evommune, Inc. announced on July 30, 2026 that the company dosed its first patient in a Phase 2b clinical trial evaluating EVO756, an oral small molecule antagonist of MRGPRX2, for prophylactic treatment of migraine.¹

The trial design calls for a global, randomized, double-blind, placebo-controlled, dose-ranging study in adults with refractory migraine who experience at least 6 migraine days per month, with roughly 330 patients randomized across two active dose arms and placebo for 12 weeks, testing daily doses up to 100 mg.¹

The primary endpoint is the mean change from baseline in monthly migraine days.¹ Secondary and exploratory measures are laid out in a section the company titled "Key secondary endpoints include the proportion of patients achieving ≥50% and ≥75% reductions in MMD, change from baseline in monthly headache days, and monthly acute migraine medication use," with additional exploratory work covering patient subtyping, biomarkers, and quality-of-life measures, according to the release.

Evommune describes EVO756's target as Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons,¹ and says the drug is designed to work through this mechanism as CEO Luis Peña called the trial initiation "an exciting milestone" for the company and for patients underserved by existing preventive therapies.¹

Top-line data from the Phase 2b trial are expected in 2027, per the release. The filing was made as an 8-K under Item 7.01, Regulation FD Disclosure, and the press release is furnished as Exhibit 99.1.